View publications by year:

2025

• Treatment Effect Estimation With Potential Outcomes for a Single-Arm Trial Compared With Historical Controls: A Case Study of Locally Recurrent Head and Neck Squamous Cell Carcinoma Patients Treated With Adjuvant Nivolumab. Harun N, Sparapani R, Laud PW, Sivaganesan S, Leddon JL, Haque S, Tang AL, Wise-Draper TM. Head Neck. 2025 Jun 17. doi: 10.1002/hed.28215.

• Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer: Insights into RTK dependent and independent mechanisms. Shyamsunder S, Lu Z, Takiar V, Waltz SE. Oncotarget. 2025 Jun 25;16:508-530.

• Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Zamulko O, Karivedu V, Riaz MK, Monroe I, Romano A, Mulanda R, Kurtzweil N, Forsythe A, Allen CL, Harun N, Pan J, Rai S, El-Gamal D, Wise-Draper TM. Cancer Res Commun. 2025 Jun 1;5(6):939-944. 

• A Single-Cell Transcriptome Atlas of Epithelial Subpopulations in HPV-Positive and HPV-Negative Head and Neck Cancers. Bedard MC, Rivera-Cruz CM, Chihanga T, VonHandorf A, Tang AL, Zender C, Weirauch MT, Ferris R, Wise-Draper TM, Adam M, Wells SI. Viruses. 2025 Mar 24;17(4):461.

2024

• Proton Treatment Suppresses Exosome Production in Head and Neck Squamous Cell Carcinoma. Chimote AA, Lehn MA, Bhati J, Mascia AE, Sertorio M, Lamba MA, Ionascu D, Tang AL, Langevin SM, Khodoun MV, Wise-Draper TM, Conforti L. Cancers (Basel). 2024 Feb 29;16(5):1008.

• A Phase 0/I Pharmacokinetic and Pharmacodynamics and Safety and Tolerability Study of Letrozole in Combination with Standard Therapy in Recurrent High-Grade Gliomas. Desai PB, Karve AS, Zawit M, Arora P, Dave N, Awosika J, Li N, Fuhrman B, Medvedovic M, Sallans L, Kendler A, DasGupta B, Plas D, Curry R, Zuccarello M, Chaudhary R, Sengupta S, Wise-Draper TM. Clin Cancer Res. 2024 May 15;30(10):2068-2077.

• Three-dimensional matrix stiffness modulates mechanosensitive and phenotypic alterations in oral squamous cell carcinoma spheroids. Sheth M, Sharma M, Lehn M, Reza H, Takebe T, Takiar V, Wise-Draper T, Esfandiari L. APL Bioeng. 2024 Jul 31;8(3):036106. 

• Multimodal assessment of high-risk human papillomavirus in sinonasal squamous cell carcinoma. Zhou A, Sharma A, Kuhnell D, Hinrichs BH, Kendler A, Wang J, Dillehey-McKillip K, Tang AL, Takiar V, Wise-Draper TM, Langevin SM. Pathol Res Pract. 2024 Sep;261:155486.

• Refining Surveillance Guidelines after Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer. Keltner S, Esslinger H, Wu X, Rai S, Takiar V. Clin Lung Cancer. 2024 Sep;25(6):e268-e276.e1. 

• Telaglenastat as an alternative to cisplatin as a radiosensitizer in the treatment of head and neck squamous cell carcinoma. Korns J, Wicker CA, Lehn M, Shyamsunder S, Thompson S, Lester C, Wise-Draper TM, Waltz SE, Takiar V. Cancer Lett. 2024 Dec 1;606:217320. 

• Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation. Hsiehchen D, Elliott A, Xiu J, Seeber A, El-Deiry W, Antonarakis ES, Graff SL, Hall MJ, Borghaei H, Hoon DSB, Liu SV, Ma PC, McKay RR, Wise-Draper T, Marshall J, Sledge GW, Spetzler D, Zhu H. Cancer Cell. 2024 Dec 9;42(12):1985-1987.

• Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial. Mell LK, Torres-Saavedra PA, Wong SJ, Kish JA, Chang SS, Jordan RC, Liu T, Truong MT, Winquist EW, Takiar V, Wise-Draper T, Robbins JR, Rodriguez CP, Awan MJ, Beadle BM, Henson C, Narayan S, Spencer SA, Powell S, Dunlap N, Sacco AG, Hu KS, Park HS, Bauman JE, Harris J, Yom SS, Le QT. Lancet Oncol. 2024 Dec;25(12):1576-1588.

2023

• Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19. Z, Labaki C, Grover P, Awosika J, Gulati S, Hsu CY, Alimohamed SI, Bashir B, Berg S, Bilen MA, Bowles D, Castellano C, Desai A, Elkrief A, Eton OE, Fecher LA, Flora D, Galsky MD, Gatti-Mays ME, Gesenhues A, Glover MJ, Gopalakrishnan D, Gupta S, Halfdanarson TR, Hayes-Lattin B, Hendawi M, Hsu E, Hwang C, Jandarov R, Jani C, Johnson DB, Joshi M, Khan H, Khan SA, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Matar S, McKay RR, Mishra S, Moria FA, Nizam A, Nock NL, Nonato TK, Panasci J, Pomerantz L, Portuguese AJ, Provenzano D, Puc M, Rao YJ, Rhodes TD, Riely GJ, Ripp JJ, Rivera AV, Ruiz-Garcia E, Schmidt AL, Schoenfeld AJ, Schwartz GK, Shah SA, Shaya J, Subbiah S, Tachiki LM, Tucker MD, Valdez-Reyes M, Weissmann LB, Wotman MT, Wulff-Burchfield EM, Xie Z, Yang YJ, Thompson MA, Shah DP, Warner JL, Shyr Y, Choueiri TK, Wise-Draper TM. JAMA oncology. 2023;9(1):128-34.
• Reflections on the 2021 Accreditation Council for Graduate Medical Education and American Board of Radiology Family and Medical Leave of Absence Policies: An Opportunity to Increase Structural Support for Physicians. Baniel CC, Klebaner D, Beadle BM, Ponce SEB, Takiar V, Gibbs IC, Soltys SG, Bagshaw HP, Chang DT, Le QT, Pollom EL. International journal of radiation oncology, biology, physics. 2023;115(1):19-22.
• Single cell transcriptomic analysis of HPV16-infected epithelium identifies a keratinocyte subpopulation implicated in cancer.Bedard MC, Chihanga T, Carlile A, Jackson R, Brusadelli MG, Lee D, VonHandorf A, Rochman M, Dexheimer PJ, Chalmers J, Nuovo G, Lehn M, Williams DEJ, Kulkarni A, Carey M, Jackson A, Billingsley C, Tang A, Zender C, Patil Y, Wise-Draper TM, Herzog TJ, Ferris RL, Kendler A, Aronow BJ, Kofron M, Rothenberg ME, Weirauch MT, Van Doorslaer K, Wikenheiser-Brokamp KA, Lambert PF, Adam M, Steven Potter S, Wells SI. Nature communications. 2023;14(1):1975.
• First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.Bendell J, LoRusso P, Overman M, Noonan AM, Kim DW, Strickler JH, Kim SW, Clarke S, George TJ, Grimison PS, Barve M, Amin M, Desai J, Wise-Draper T, Eck S, Jiang Y, Khan AA, Wu Y, Martin P, Cooper ZA, Elgeioushi N, Mueller N, Kumar R, Patel SP. Cancer immunology, immunotherapy : CII. 2023.
• PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck Chemoradiotherapy.Bonomi M, Blakaj DM, Kabarriti R, Colvett K, Takiar V, Biagioli M, Bar-Ad V, Goyal S, Muzyka B, Niermann K, Abrouk N, Oronsky B, Reid T, Caroen S, Sonis S, Sher DJ. International journal of radiation oncology, biology, physics. 2023.
• Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium.Choueiri TK, Labaki C, Bakouny Z, Hsu CY, Schmidt AL, de Lima Lopes G, Jr., Hwang C, Singh SRK, Jani C, Weissmann LB, Griffiths EA, Halabi S, Wu U, Berg S, O'Connor TE, Wise-Draper TM, Panagiotou OA, Klein EJ, Joshi M, Yared F, Dutra MS, Gatson NTN, Blau S, Singh H, Nanchal R, McKay RR, Nonato TK, Quinn R, Rubinstein SM, Puc M, Mavromatis BH, Vikas P, Faller B, Zaren HA, Del Prete S, Russell K, Reuben DY, Accordino MK, Singh H, Friese CR, Mishra S, Rivera DR, Shyr Y, Farmakiotis D, Warner JL. Lancet regional health Americas. 2023;19:100445.
• Small extravesicular microRNA in head and neck squamous cell carcinoma and its potential as a liquid biopsy for early detection. Galiveti CR, Kuhnell D, Biesiada J, Zhang X, Kelsey KT, Takiar V, Tang AL, Wise-Draper TM, Medvedovic M, Kasper S, Langevin SM. Head & neck. 2023;45(1):212-24.
• Durvalumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, non-randomized, phase-2 clinical trial.Gulati S, Crist M, Riaz MK, Takiar V, Lehn M, Monroe I, Palackdharry S, Kurtzweil N, Jandarov R, Harun N, Wise-Draper TM. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023.
• Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma.Johnson DB, Atkins MB, Hennessy C, Wise-Draper T, Heilman H, Awosika J, Bakouny Z, Labaki C, Saliby RM, Hwang C, Singh SRK, Balanchivadze N, Friese CR, Fecher LA, Yoon JJ, Hayes-Lattin B, Bilen MA, Castellano CA, Lyman GH, Tachiki L, Shah SA, Glover MJ, Flora DB, Wulff-Burchfield E, Kasi A, Abbasi SH, Farmakiotis D, Viera K, Klein EJ, Weissman LB, Jani C, Puc M, Fahey CC, Reuben DY, Mishra S, Beeghly-Fadiel A, French B, Warner JL. BMC Cancer. 2023;23(1):265.
• Varied Photon Radiation Sources Produce Differences in Cellular Response.Korns J, McCauley S, Lehn M, Takiar V, Sertorio M, Lamba M. Radiation research. 2023;199(4):422-8.
• Editorial: The relationship between COVID-19 severity and cancer immunity and immunotherapy. JA, Wise-Draper TM, Lambert C. Frontiers in immunology. 2023;14:1184007.
• A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia. KW, Kaplan J, Levy M, Bixby D, Burke PW, Erba H, Wise-Draper TM, Roboz GJ, Papadantonakis N, Rajkhowa T, Hernandez D, Dobler I, Gregory RC, Li C, Wang S, Stumpo K, Kannan K, Miao H, Levis M. Haematologica. 2023;108(3):705-16.
• Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline.Yilmaz E, Ismaila N, Bauman JE, Dabney R, Gan G, Jordan R, Kaufman M, Kirtane K, McBride SM, Old MO, Rooper L, Saba NF, Sheth S, Subramaniam RM, Wise-Draper TM, Wong D, Mell LK. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023;41(5):1132-46.

2022

• Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer. Bauman, J. E., R. Julian, N. F. Saba, T. M. Wise-Draper, D. R. Adkins, P. O'Brien, M. J. Fidler, M. K. Gibson, U. Duvvuri, M. Heath-Chiozzi, D. Alvarado, R. Gedrich, P. Golden, and R. B. Cohen. Cancers (Basel) 14, no. 10 (May 10 2022). http://dx.doi.org/10.3390/cancers14102355.
• Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer.Deneka, A. Y., Y. Baca, I. G. Serebriiskii, E. Nicolas, M. I. Parker, T. T. Nguyen, J. Xiu, W. M. Korn, M. J. Demeure, T. Wise-Draper, A. Sukari, B. Burtness, and E. A. Golemis. Clin Cancer Res 28, no. 9 (May 2 2022): 1925-37. http://dx.doi.org/10.1158/1078-0432.Ccr-21-4316.
• Therapeutic Advancements in Metal and Metal Oxide Nanoparticle-Based Radiosensitization for Head and Neck Cancer Therapy. Dubey, P., M. Sertorio, and V. Takiar. Cancers (Basel) 14, no. 3 (Jan 20 2022). http://dx.doi.org/10.3390/cancers14030514.
• Geriatric Risk Factors for Serious Covid-19 Outcomes among Older Adults with Cancer: A Cohort Study from the Covid-19 and Cancer Consortium.Elkrief, A., C. Hennessy, N. M. Kuderer, S. M. Rubinstein, E. Wulff-Burchfield, R. P. Rosovsky, K. Vega-Luna, M. A. Thompson, O. A. Panagiotou, A. Desai, D. R. Rivera, A. R. Khaki, L. Tachiki, R. C. Lynch, C. Stratton, R. Elias, G. Batist, A. Kasi, D. P. Shah, Z. Bakouny, A. Cabal, J. Clement, J. Crowell, B. Dixon, C. R. Friese, S. L. Fry, P. Grover, S. Gulati, S. Gupta, C. Hwang, H. Khan, S. J. Kim, E. J. Klein, C. Labaki, R. R. McKay, A. Nizam, N. A. Pennell, M. Puc, A. L. Schmidt, A. Shahrokni, J. A. Shaya, C. T. Su, S. Wall, N. Williams,T. M. Wise-Draper, S. Mishra, P. Grivas, B. French, J. L. Warner, and T. M. Wildes. Lancet Healthy Longev 3, no. 3 (Mar 2022): e143-e52. http://dx.doi.org/10.1016/s2666-7568(22)00009-5.
• A Phase I/II Trial of Concurrent Immunotherapy with Chemoradiation in Locally Advanced Larynx Cancer.Frankart, A. J., N. H. Sadraei, B. Huth, K. P. Redmond, W. L. Barrett, N. Kurtzweil, M. K. Riaz,T. Wise-Draper, C. P. Rodriguez, D. J. Adelstein, andV. Takiar. Laryngoscope Investig Otolaryngol 7, no. 2 (Apr 2022): 437-43. http://dx.doi.org/10.1002/lio2.780.
• Racial Disparities in Covid-19 Outcomes among Black and White Patients with Cancer.Fu, J., S. A. Reid, B. French, C. Hennessy, C. Hwang, N. T. Gatson, N. Duma, S. Mishra, R. Nguyen, J. E. Hawley, S. R. K. Singh, D. D. Chism, N. K. Venepalli, J. L. Warner, T. K. Choueiri, A. L. Schmidt, L. A. Fecher, J. E. Girard, M. A. Bilen, D. Ravindranathan, S. Goyal,T. M. Wise-Draper, C. Park, C. A. Painter, S. M. McGlown, G. de Lima Lopes, Jr., O. K. Serrano, and D. P. Shah. JAMA Netw Open 5, no. 3 (Mar 1 2022): e224304. http://dx.doi.org/10.1001/jamanetworkopen.2022.4304.
• A Review of Plks: Thinking Outside the (Polo) Box.Korns, J., X. Liu, andV. Takiar. Mol Carcinog 61, no. 2 (Feb 2022): 254-63. http://dx.doi.org/10.1002/mc.23388.
• Reirradiation of Recurrent and Second Primary Cancers of the Head and Neck: A Review of the Contemporary Evidence.Kreinbrink, P. J., L. M. Lewis, K. P. Redmond, andV. Takiar. Curr Treat Options Oncol 23, no. 3 (Mar 2022): 295-310. http://dx.doi.org/10.1007/s11864-021-00936-y.
• Phase 2 Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck.Leddon, J. L., S. Gulati, S. Haque, C. Allen, S. Palackdharry, M. Mathews, N. Kurtzweil, M. K. Riaz,V. Takiar, M. Nagasaka, Y. Patil, C. Zender, A. Tang, B. Cervenka, J. McGrath, W. M. Korn, B. H. Hinrichs, R. Jandarov, N. Harun, A. Sukari, andT. M. Wise-Draper. Clin Cancer Res (Jun 2 2022). http://dx.doi.org/10.1158/1078-0432.Ccr-21-4554.
• Intensity Modulated Proton Therapy Better Spares Non-Adjacent Organs and Reduces the Risk of Secondary Malignant Neoplasms in the Treatment of Sinonasal Cancers.Lewis, L., P. Kreinbrink, M. Richardson, M. Westerfield, M. Doberstein, Y. Zhang, K. Redmond, andV. Takiar. Med Dosim 47, no. 2 (Summer 2022): 117-22. http://dx.doi.org/10.1016/j.meddos.2021.11.002.
• Patients Recently Treated for B-Lymphoid Malignancies Show Increased Risk of Severe Covid-19.Rubinstein, S. M., D. Bhutani, R. C. Lynch, C. Y. Hsu, Y. Shyr, S. Advani, R. A. Mesa, S. Mishra, D. P. Mundt, D. P. Shah, R. A. Sica, K. E. Stockerl-Goldstein, C. Stratton, M. Weiss, A. Beeghly-Fadiel, M. Accordino, S. E. Assouline, J. Awosika, Z. Bakouny, B. Bashir, S. Berg, M. A. Bilen, C. A. Castellano, J. C. Cogan, D. Kc, C. R. Friese, S. Gupta, D. Hausrath, C. Hwang, N. A. Johnson, M. Joshi, A. Kasi, E. J. Klein, V. S. Koshkin, N. M. Kuderer, D. H. Kwon, C. Labaki, T. Latif, E. Lau, X. Li, G. H. Lyman, R. R. McKay, G. Nagaraj, A. Nizam, T. K. Nonato, A. J. Olszewski, H. V. Polimera, A. J. Portuguese, M. M. Puc, P. Razavi, R. Rosovski, A. Schmidt, S. A. Shah, A. Shastri, C. Su, P. Torka,T. M. Wise-Draper, L. Zubiri, J. L. Warner, and M. A. Thompson. Blood Cancer Discov 3, no. 3 (May 5 2022): 181-93. http://dx.doi.org/10.1158/2643-3230.Bcd-22-0013.
• Coinfections in Patients with Cancer and Covid-19: A Covid-19 and Cancer Consortium (Ccc19) Study.Satyanarayana, G., K. T. Enriquez, T. Sun, E. J. Klein, M. Abidi, S. M. Advani, J. Awosika, Z. Bakouny, B. Bashir, S. Berg, M. Bernardes, P. C. Egan, A. Elkrief, L. E. Feldman, C. R. Friese, S. Goel, C. G. Gomez, K. L. Grant, E. A. Griffiths, S. Gulati, S. Gupta, C. Hwang, J. Jain, C. Jani, A. Kaltsas, A. Kasi, H. Khan, N. Knox, V. S. Koshkin, D. H. Kwon, C. Labaki, G. H. Lyman, R. R. McKay, C. McNair, G. Nagaraj, E. S. Nakasone, R. Nguyen, T. K. Nonato, A. J. Olszewski, O. A. Panagiotou, M. Puc, P. Razavi, E. V. Robilotti, M. Santos-Dutra, A. L. Schmidt, D. P. Shah, S. A. Shah, K. Vieira, L. B. Weissmann,T. M. Wise-Draper, U. Wu, J. T. Wu, T. K. Choueiri, S. Mishra, J. L. Warner, B. French, and D. Farmakiotis. Open Forum Infect Dis 9, no. 3 (Mar 2022): ofac037. http://dx.doi.org/10.1093/ofid/ofac037.
• Hospital Price Transparency Rule Exposes Muddied Costs for Head and Neck Radiotherapy in One State.Thompson, S., L. Lewis, andV. Takiar. Am J Clin Oncol 45, no. 6 (Jun 1 2022): 268-72.http://dx.doi.org/10.1097/coc.0000000000000917.
• Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges.Wise-Draper, T. M., H. Bahig, V. Karivedu, and B. Burtness. Am Soc Clin Oncol Educ Book 42 (Apr 2022): 1-14. http://dx.doi.org/10.1200/edbk_350442.
• Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma.Wise-Draper, T. M., S. Gulati, S. Palackdharry, B. H. Hinrichs, F. P. Worden, M. O. Old, N. E. Dunlap, J. M. Kaczmar, Y. Patil, M. K. Riaz, A. Tang, J. Mark, C. Zender, A. M. Gillenwater, D. Bell, N. Kurtzweil, M. Mathews, C. L. Allen, M. L. Mierzwa, K. Casper, R. Jandarov, M. Medvedovic, J. J. Lee, N. Harun, V. Takiar, and M. Gillison. Clin Cancer Res 28, no. 7 (Apr 1 2022): 1345-52. http://dx.doi.org/10.1158/1078-0432.Ccr-21-3351.
• A review of Plks: Thinking outside the (polo) box. Korns J, Liu X, Takiar V. Mol Carcinog. 2022 Jan 20. doi: 10.1002/mc.23388. Epub ahead of print. PMID: 35049091.

2021

• Osteoradionecrosis: Exposing the evidence not the bone. Frankart AJ, Frankart MJ, Cervenka B, Tang AL, Krishnan DG, Takiar V. International journal of radiation oncology, biology, physics 2021 Jan 4.
• Increased pain reporting by head and neck cancer patients at radiation oncology consultation: A quality-of-life analysis.Havard M, Esslinger H, Mierzwa M, Kharofa J,Takiar V.The Laryngoscope. 2021 Feb;131(2):326-332.
• Targeted knockdown of the adenosine A2A receptor by lipid NPs rescues the chemotaxis of head and neck cancer memory T cells. Newton HS, Chimote AA, Arnold MJ, Wise-Draper TM, Conforti L. Mol Ther Methods Clin Dev. 2021 Mar 4;21:133-143.
• Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models. Wicker CA, Hunt BG, Krishnan S, Aziz K, Parajuli S, Palackdharry S, Elaban WR, Wise-Draper TM, Mills GB, Waltz SE, Takiar V. Cancer Lett. 2021 Apr 1;502:180-188.
• Assessing the Reliability and Positive Predictive Value of p16 as a Surrogate for Human Papillomavirus-Mediated E6/7 mRNA Expression in Squamous Cell Carcinoma of the Anal Canal. Frankart AJ, Criss BE, Dillehay McKillip K, Wise-Draper T, Takiar V, Kharofa J. Dis Colon Rectum. 2021 Apr 1;64(4):459-465.
• Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial. Adkins DR, Lin JC, Sacco A, Ley J, Oppelt P, Vanchenko V, Komashko N, Yen CJ, Wise-Draper T, Lopez-Picazo Gonzalez J, Radulovic S, Shen Q, Thurm H, Martini JF, Hoffman J, Huang X, Melichar B, Tahara M. Oral Oncol. 2021 Apr;115:105192.
• The Absolute Lymphocyte Count as a Prognostic Marker in Oropharyngeal Head and Neck Squamous Cell Carcinoma. Kreinbrink PJ, Li J, Parajuli S, Wise-Draper TM, Takiar V. Oral Oncology. 2021 May;116:105245.
• Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Grivas P, Khaki AR, Wise-Draper TM, et al. Ann Oncol. 2021 Jun;32(6):787-800.
• Hypothyroidism Incidence Does Not Change with the Addition of Immune Checkpoint Inhibitors in Patients with Head and Neck Squamous Cell Carcinoma. Leddon JL, Chirra M, Frankart A, Agrawal A, Roof L, Trotier D, Shaikh H, Stone T, Jandarov R, Takiar V, Wise-Draper TM. Laryngoscope. 2021 Jul;131(7):E2413-E2419.
• Recommendations for Postoperative Radiotherapy in Head & Neck Squamous Cell Carcinoma in the Presence of Flaps: A GORTEC Internationally-Reviewed HNCIG-Endorsed Consensus. Carsuzaa F…Takiar V…Thariat J. Radiother and Oncology. 2021 Jul;160:140-147.
• Human Papillomavirus and Survival of Sinonasal Squamous Cell Carcinoma Patients: A Systematic Review and Meta-Analysis. Cancers (Basel). Sharma A, Tang AL, Takiar V, Wise-Draper TM, Langevin SM. 2021 Jul 22;13(15):3677.
• Immune Checkpoint Inhibitors Regulate K+ Channel Activity in Cytotoxic T Lymphocytes of Head and Neck Cancer Patients. Gawali VS, Chimote AA, Newton HS, Feria-Garzón MG, Chirra M, Janssen EM, Wise-Draper TM, Conforti L. Front Pharmacol. 2021 Aug 27;12:742862.
• Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients. Clancy K, Hamill CS, O'Neill WQ, Vu B, Thuener J, Gui S, Li S, Fowler N, Rezaee R, Lavertu P, Wasman J, Patel M, Shaikh H, Vick E, Madabhushi A, Wise-Draper TM, Burkitt K, Teknos TN, Pan Q. Cancers (Basel). 2021 Sep 28;13(19):4861.
• In Reply to Laurent et al. Frankart AJ, Takiar V. Int J Radiat Oncol Biol Phys. 2021 Oct 1;111(2):584.
• Managing Recurrent Metastatic Head and Neck Cancer. Shaikh H, Karivedu V, Wise-Draper TM. Hematol Oncol Clin North Am. 2021 Oct;35(5):1009-1020.
• Modified Head and Neck Swallow Scale: Using EORTC-QLQ-H&N35 to Predict Overall Survival. VonAllmen D, Tang A, Takiar V, Zender C, Romeo S, Masch J, Casper K, Patil Y, Wilson K, Khosla S, Niu L, Altaye M, Tabangin M, Howell RJ. Laryngoscope. 2021 Nov;131(11):2478-2482.
• Adjuvant radiation and cetuximab improves local control in head and neck cutaneous squamous cell carcinoma: Phase II study. Kreinbrink PJ, Mierzwa ML, Huth B, Redmond KP, Wise-Draper TM, Casper K, Li J, Takiar V. Head Neck. 2021 Nov;43(11):3408-3416.
• Multi-Institutional Study Validates Safety of Intraoperative Cesium-131 Brachytherapy for Treatment of Recurrent Head and Neck Cancer. Luginbuhl A, Calder A, Kutler D, Zender C, Wise-Draper T, Patel J, Cheng M, Karivedu V, Zhan T, Parashar B, Gulati S, Yao M, Lavertu P, Takiar V, Tang A, Johnson J, Keane W, Curry J, Cognetti D, Bar-Ad V. Front Oncol. 2021 Nov 26;11:786216.
• Trends in women speakers at the American Head and Neck Society Meetings from 2007-2019. Brandi MH, Howell R, Power A, Tabangin M, Altaye M, Zender C, Takiar V, Tang A. JAMA Otolaryngology – Head and Neck Surgery. 2021. JAMA Otolaryngol Head Neck Surg. 2021 Dec 1;147(12):1053-1058.
• Intensity Modulated Proton Therapy Better Spares Non-Adjacent Organs and Reduces the Risk of Secondary Malignant Neoplasms in the Treatment of Sinonasal Cancers. Lewis L, Kreinbrink P, Richardson M, Westerfield M, Doberstein M, Zhang Y, Redmond K, Takiar V. Med Dosim. 2021 Dec 21:S0958-3947(21)00104-7.
• Genomic and Molecular Profiling of Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma Treated with Immune Checkpoint Blockade Compared to Survival Outcomes. Shaikh H, McGrath JE, Hughes B, Xiu J, Brodskiy P, Sukari A, Darabi S, Ikpeazu C, Nabhan C, Korn WM, Wise-Draper TM. Cancers (Basel). 2021 Dec 16;13(24):6309.

2020

• Female Representation in Otolaryngology Leadership Roles. Epperson M, Gouveia CJ, Tabangin ME, Takiar V, Howell R, Altaye M, Ishman SL, Tang AL. The Laryngoscope. 2020;130(7):1664-1669.
• Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer. Gulati S, Desai J, Palackdharry SM, Morris JC, Zhu Z, Jandarov R, Riaz MK, Takiar V, Mierzwa M, Gutkind JS, Molinolo A, Desai PB, Sadraei NH, Wise-Draper TM. Cancer 2020;126:354-362.
• MST1R (ron) expression is a novel prognostic biomarker for metastatic progression in breast cancer patients. Hunt BG, Wicker CA, Bourn JR, Lower EE, Takiar V, Waltz SE. Breast cancer research and treatment 2020.
• Determining the molecular landscape and impact on prognosis in hpv-associated head and neck cancer. Khanna S, Palackdharry S, Roof L, Wicker CA, Mark J, Zhu Z, Jandorav R, Molinolo A, Takiar V, Wise-Draper TM. Cancers of the Head & Neck 2020;5:11.
• Successful use of a therapeutic trial of graduated volume and dose escalation for postoperative head and neck radiotherapy in a fanconi anemia patient. Lewis LM, Tang AL, Wise-Draper TM, Myers KC, Greenberger JS, Takiar V. Head & neck 2020 Oct;42(10):E16-E22.
• In reference to the psychological impact of head and neck cancer in pain perception. Takiar V. The Laryngoscope 2020.
• Body mass index and age affect maximum mouth opening in a contemporary american population. Venkatraman A, Kaval F, Takiar V. Journal of oral and maxillofacial surgery: official journal of the American Association of Oral and Maxillofacial Surgeons 2020.
• Evaluation of antioxidant network proteins as novel prognostic biomarkers for head and neck cancer patients. Wicker CA, Takiar V, Suganya R, Arnold SM, Brill YM, Chen L, Horbinski CM, Napier D, Valentino J, Kudrimoti MR, Yu G, Izumi T. Oral oncology 2020;Dec;111:104949.
• Defining the dose-volume criteria for laryngeal sparing in locally advanced oropharyngeal cancer utilizing split-field IMRT, whole-field IMRT and VMAT. Wilke C, Takiar V, Wang H, Moreno AC, Tung S-MS, Quinlan-Davidson SR, Garden AS, Rosenthal DI, Fuller CD, Gunn GB, Reddy JP, Morrison WH, Wang C, Zhao G, Hutcheson KA, Phan J. Journal of applied clinical medical physics 2020.
• PD1 blockade enhances K⁺channel activity, Ca²⁺signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancer. Newton HS, Gawali VS, Chimote AA, Lehn MA, Palackdharry SM, Hinrichs BH, Jandarov R, Hildeman D, Janssen EM, Wise-Draper TM, Conforti L. J Immunother Cancer. 2020 Oct;8(2):e000844. doi: 10.1136/jitc-2020-000844. PMID: 33060146; PMCID: PMC7566435.
• COVID-19 pandemic and impact on cancer clinical trials: An academic medical center perspective. Marcum M, Kurtzweil N, Vollmer C, Schmid L, Vollmer A, Kastl A, Acker K, Gulati S, Grover P, Herzog TJ, Ahmad SA, Sohal D, Wise-Draper TM. Cancer Med. 2020 Sep;9(17):6141-6146. doi: 10.1002/cam4.3292. Epub 2020 Jul 10. PMID: 32648667; PMCID: PMC7404529.
• Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer. Le X, Ferrarotto R, Wise-Draper T, Gillison M. J Natl Compr Canc Netw. 2020 Jul;18(7):899-906. doi: 10.6004/jnccn.2020.7590. PMID: 32634775.
• CD244 represents a new therapeutic target in head and neck squamous cell carcinoma. Agresta L, Lehn M, Lampe K, Cantrell R, Hennies C, Szabo S, Wise-Draper T, Conforti L, Hoebe K, Janssen EM. J Immunother Cancer. 2020 Mar;8(1):e000245. doi: 10.1136/jitc-2019-000245. PMID: 32217758; PMCID: PMC7174077.
• Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Tsurutani J, Iwata H, Krop I, Jänne PA, Doi T, Takahashi S, Park H, Redfern C, Tamura K, Wise-Draper TM, Saito K, Sugihara M, Singh J, Jikoh T, Gallant G, Li BT. Cancer Discov. 2020 May;10(5):688-701. doi: 10.1158/2159-8290.CD-19-1014. Epub 2020 Mar 25. Erratum in: Cancer Discov. 2020 Jul;10(7):1078. PMID: 32213540.
• A Compartmentalized Reduction in Membrane-Proximal Calmodulin Reduces the Immune Surveillance Capabilities of CD8⁺T Cells in Head and Neck Cancer. Chimote AA, Gawali VS, Newton HS, Wise-Draper TM, Conforti L. Front Pharmacol. 2020 Feb 28;11:143. doi: 10.3389/fphar.2020.00143. PMID: 32184726; PMCID: PMC7059094.

2019

• Whiteboard patient tracking system improves radiation oncology treatment planning workflow. Freese C, Forster N, Prater B, Amlung M, Lamba M, Takiar V. Journal of Radiation Oncology 2019;8:177-183.
• Optimizing laryngeal sparing with intensity modulated radiotherapy or volumetric modulated arc therapy for unilateral tonsil cancer. Moreno AC, Wilke C, Wang H, Tung S-MS, Pollard C, III, Garden AS, Morrison WH, Rosenthal DI, Fuller CD, Gunn GB, Reddy JP, Shah SJ, Frank SJ, Takiar V, Phan J. Physics and Imaging in Radiation Oncology 2019;10:29-34.
• IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma. Kofuji S, Hirayama A, Eberhardt AO, Kawaguchi R, Sugiura Y, Sampetrean O, Ikeda Y, Warren M, Sakamoto N, Kitahara S, Yoshino H, Yamashita D, Sumita K, Wolfe K, Lange L, Ikeda S, Shimada H, Minami N, Malhotra A, Morioka S, Ban Y, Asano M, Flanary VL, Ramkissoon A, Chow LML, Kiyokawa J, Mashimo T, Lucey G, Mareninov S, Ozawa T, Onishi N, Okumura K, Terakawa J, Daikoku T, Wise-Draper T, Majd N, Kofuji K, Sasaki M, Mori M, Kanemura Y, Smith EP, Anastasiou D, Wakimoto H, Holland EC, Yong WH, Horbinski C, Nakano I, DeBerardinis RJ, Bachoo RM, Mischel PS, Yasui W, Suematsu M, Saya H, Soga T, Grummt I, Bierhoff H, Sasaki AT. Nat Cell Biol. 2019 Aug;21(8):1003-1014. doi: 10.1038/s41556-019-0363-9. Epub 2019 Aug 1. PMID: 31371825; PMCID: PMC6686884.
• Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013. Ribrag V, Avigan DE, Green DJ, Wise-Draper T, Posada JG, Vij R, Zhu Y, Farooqui MZH, Marinello P, Siegel DS. Br J Haematol. 2019 Aug;186(3):e41-e44. doi: 10.1111/bjh.15888. Epub 2019 Apr 1. PMID: 30937889.
• High-risk pathological features at the time of salvage surgery predict poor survival after definitive therapy in patients with head and neck squamous cell carcinoma.Haque S, Karivedu V, Riaz MK, Choi D, Roof L, Hassan SZ, Zhu Z, Jandarov R,Takiar V, Tang A,Wise-Draper T. Oral Oncol. 2019 Jan;88:9-15.

2018

• Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in a Case-Control Study of Patients with Head and Neck Squamous Cell Carcinoma. Wise-Draper T, Sendilnathan A, Palackdharry S, Pease N, Qualtieri J, Butler R, Sadraei NH, Morris JC, Patil Y, Wilson K, Mark J, Casper K, Takiar V, Lane A, Privette Vinnedge L. Transl Oncol. 2018 Feb;11(1):168-174.
• A defect in KCa3.1 channel activity limits the ability of CD8₊ T cells from cancer patients to infiltrate an adenosine-rich microenvironment.Chimote AA, Balajthy A, Arnold MJ, Newton HS, Hajdu P, Qualtieri J, Wise-Draper T, Conforti L. Sci Signal. 2018 Apr 24;11(527).
• Debulking surgery of pituitary adenoma as a strategy to facilitate definitive stereotactic radiosurgery. Forster N, Warnick R, Takiar V, Pater L, Breneman J. J Neurooncol. 2018 Jun;138(2):335-340.
• Differential expression and prognostic value of long non-coding RNA in HPV-negative head and neck squamous cell carcinoma. Haque SU, Niu L, Kuhnell D, Hendershot J, Biesiada J, Niu W, Hagan MC, Kelsey KT, Casper KA, Wise-Draper TM, Medvedovic M, Langevin SM. Head Neck. 2018 Jul;40(7):1555-1564.
• Maternity and paternity leave in otolaryngology residency training in the United States. Tang AL, Miller A, Hauff S, Myer CM 3rd, Takiar V, Howell RJ, Mark JR. Laryngoscope. 2018 Oct 12.

2017

• Kv1.3 Channels Mark Functionally Competent CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Cancer. Chimote AA, Hajdu P, Sfyris AM, Gleich BN, Wise-Draper T, Casper KA, Conforti L. Cancer Res. 2017 Jan 1;77(1):53-61.
• Radiation and subsequent reirradiation outcomes in the treatment of diffuse intrinsic pontine glioma and a systematic review of the reirradiation literature. Freese C, Takiar V, Fouladi M, DeWire M, Breneman J, Pater L.Pract Radiat Oncol. 2017 Mar - Apr;7(2):86-92.
• Neomorphic mutations create therapeutic challenges in cancer. Takiar V, Ip CK, Gao M, Mills GB, Cheung LW. Oncogene. 2017 Mar 23;36(12):1607-1618. Review.
• Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells. Tuttle TR, Takiar V, Kumar B, Kumar P, Ben-Jonathan N. Cancer Lett. 2017 Mar 28;389:33-40.
• A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies. Wise-Draper TM, Moorthy G, Salkeni MA, Karim NA, Thomas HE, Mercer CA, Beg MS, O'Gara S, Olowokure O, Fathallah H, Kozma SC, Thomas G, Rixe O, Desai P, Morris JC. Target Oncol. 2017 Jun;12(3):323-332.
• Comprehensive microRNA-sequencing of exosomes derived from head and neck carcinoma cells in vitro reveals common secretion profiles and potential utility as salivary biomarkers. Langevin S, Kuhnell D, Parry T, Biesiada J, Huang S, Wise-Draper T, Casper K, Zhang X, Medvedovic M, Kasper S. Oncotarget. 2017 Jul 27;8(47):82459-82474.

2016

• Orbital carcinomas treated with adjuvant intensity-modulated radiation therapy.Tao R, Ma D, Takiar V, Frank SJ, Fuller CD, Gunn GB, Beadle BM, Morrison WH, Rosenthal DI, Edson MA, Esmaeli B, Kupferman ME, Hanna EY, Garden AS, Phan J.Head Neck. 2016 Apr;38 Suppl 1:E580-7.
• Disease control and toxicity outcomes for T4 carcinoma of the nasopharynx treated with intensity-modulated radiotherapy. Takiar V, Ma D, Garden AS, Li J, Rosenthal DI, Beadle BM, Frank SJ, Fuller CD, Gunn GB, Morrison WH, Hutcheson K, El-Naggar AK, Gold KA, Kupferman ME, Phan J. Head Neck. 2016 Apr;38 Suppl 1:E925-33.
• Outcomes for hypopharyngeal carcinoma treated with organ-preservation therapy. Edson MA, Garden AS, Takiar V, Glisson BS, Fuller CD, Gunn GB, Beadle BM, Morrison WH, Frank SJ, Shah SJ, Tao R, William WN, Weber RS, Rosenthal DI, Phan J. Head Neck. 2016 Apr;38 Suppl 1:E2091-9.
• Improved setup and positioning accuracy using a three-point customized cushion/mask/bite-block immobilization system for stereotactic reirradiation of head and neck cancer. Wang H, Wang C, Tung S, Dimmitt AW, Wong PF, Edson MA, Garden AS, Rosenthal DI, Fuller CD, Gunn GB, Takiar V, Wang XA, Luo D, Yang JN, Wong J, Phan J. J Appl Clin Med Phys. 2016 May 8;17(3):180-189.
• Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT. Mitra S, Federico L, Zhao W, Dennison J, Sarkar TR, Zhang F, Takiar V, Cheng KW, Mani S, Lee JS, Mills GB. Oncotarget. 2016 Jun 28;7(26):40252-40265.
• Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses. Takiar V, Garden AS, Ma D, Morrison WH, Edson M, Zafereo ME, Gunn GB, Fuller CD, Beadle B, Frank SJ, William WN Jr, Kies M, El-Naggar AK, Weber R, Rosenthal DI, Phan J.Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1117-31.
• The current status of oncolytic viral therapy for head and neck cancer. Old MO, Wise-Draper T, Wright CL, Kaur B, Teknos T. World J Otorhinolaryngol Head Neck Surg. 2016 Jul 22;2(2):84-89.
• Treatment of early stage vaginal cancer with EBRT and MRI-based intracavitary brachytherapy: A retrospective case review. Damast S, Takiar V, McCarthy S, Higgins SA. Gynecol Oncol Rep. 2016 Aug 4;17:89-92.
• Reirradiation of Head and Neck Cancers With Proton Therapy: Outcomes and Analyses. Phan J, Sio TT, Nguyen TP, Takiar V, Gunn GB, Garden AS, Rosenthal DI, Fuller CD, Morrison WH, Beadle B, Ma D, Zafereo ME, Hutcheson KA, Kupferman ME, William WN Jr, Frank SJ. Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):30-41.
• The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer. Riaz MK, Bal S, Wise-Draper T. J Surg Oncol. 2016 Sep;114(3):323-8. Review.

2015

• Dissecting the Potential Interplay of DEK Functions in Inflammation and Cancer. Pease NA, Wise-Draper T, Privette Vinnedge L. J Oncol. 2015;2015:106517. Review.
• DEK promotes HPV-positive and -negative head and neck cancer cell proliferation. Adams AK, Hallenbeck GE, Casper KA, Patil YJ, Wilson KM, Kimple RJ, Lambert PF, Witte DP, Xiao W, Gillison ML, Wikenheiser-Brokamp KA, Wise-Draper TM, Wells SI. Oncogene. 2015 Feb 12;34(7):868-77.
• A choice of radionuclide: Comparative outcomes and toxicity of ruthenium-106 and iodine-125 in the definitive treatment of uveal melanoma. Takiar V, Voong KR, Gombos DS, Mourtada F, Rechner LA, Lawyer AA, Morrison WH, Garden AS, Beadle BM. Pract Radiat Oncol. 2015 May-Jun;5(3):e169-76.
• Oncolytic virotherapy for head and neck cancer: current research and future developments. Malhotra A, Sendilnathan A, Old MO, Wise-Draper TM. Oncolytic Virother. 2015 Jul 20;4:83-93. Review.

2014

• MRI-based sector analysis enhances prostate palladium-103 brachytherapy quality assurance in a phase II prospective trial of men with intermediate-risk localized prostate cancer.Takiar V, Pugh TJ, Swanson D, Kudchadker RJ, Bruno TL, McAvoy S, Mahmood U, Frank SJ. Brachytherapy. 2014 Jan-Feb;13(1):68-74.
• Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. Takiar V, Akay CL, Stauder MC, Tereffe W, Alvarez RH, Hoffman KE, Perkins GH, Strom EA, Buchholz TA, Ueno NT, Babiera G, Woodward WA. Springerplus. 2014 Mar 31;3:166.
• Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Hoffman KE, Voong KR, Pugh TJ, Skinner H, Levy LB, Takiar V, Choi S, Du W, Frank SJ, Johnson J, Kanke J, Kudchadker RJ, Lee AK, Mahmood U, McGuire SE, Kuban DA. Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1074-84.
• Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma. Takiar V, Gombos DS, Mourtada F, Rechner LA, Lawyer AA, Morrison WH, Garden AS, Beadle BM. Pract Radiat Oncol. 2014 Jul-Aug;4(4):e189-94.
• Human papillomavirus induced transformation in cervical and head and neck cancers. Adams AK, Wise-Draper TM, Wells SI. Cancers (Basel). 2014 Sep 15;6(3):1793-820. Review.
• Lymphoma presenting as secondary HLH: a review with a tale of two cases. Ghose A, Yellu M, Wise-Draper T, Sharma D, Qualtieri J, Latif T, Medlin S. Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):e187-93. Review.

Prior to 2014

• A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer. Bahassi el M, Li YQ, Wise-Draper TM, Deng L, Wang J, Darnell CN, Wilson KM, Wells SI, Stambrook PJ, Rixe O. Eur J Cancer. 2013 Jul;49(10):2345-55.
• Anatomic distribution of fluorodeoxyglucose-avid para-aortic lymph nodes in patients with cervical cancer.Takiar V, Fontanilla HP, Eifel PJ, Jhingran A, Kelly P, Iyer RB, Levenback CF, Zhang Y, Dong L, Klopp A. Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1045-50.
• Anatomic distribution of [(18)F] fluorodeoxyglucose-avid lymph nodes in patients with cervical cancer. Fontanilla HP, Klopp AH, Lindberg ME, Jhingran A, Kelly P, Takiar V, Iyer RB, Levenback CF, Zhang Y, Dong L, Eifel PJ. Pract Radiat Oncol. 2013 Jan-Mar;3(1):45-53.
• Locoregional interaction of ixabepilone (ixempra) after breast cancer radiation.Takiar V, Strom EA, Baumann DP, Meric-Bernstam F, Alvarez RH, Gonzalez-Angulo AM. Oncologist. 2013;18(3):265-70.
• VIP17/MAL expression modulates epithelial cyst formation and ciliogenesis. Takiar V, Mistry K, Carmosino M, Schaeren-Wiemers N, Caplan MJ. Am J Physiol Cell Physiol. 2012 Oct 15;303(8):C862-71.
• Future directions and treatment strategies for head and neck squamous cell carcinomas. Wise-Draper TM, Draper DJ, Gutkind JS, Molinolo AA, Wikenheiser-Brokamp KA, Wells SI. Transl Res. 2012 Sep;160(3):167-77.
• Polycystic kidney disease: pathogenesis and potential therapies.Takiar V, Caplan MJ. Biochim Biophys Acta. 2011 Oct;1812(10):1337-43. Review.
• The human DEK oncogene regulates DNA damage response signaling and repair. Kavanaugh GM, Wise-Draper TM, Morreale RJ, Morrison MA, Gole B, Schwemberger S, Tichy ED, Lu L, Babcock GF, Wells JM, Drissi R, Bissler JJ, Stambrook PJ, Andreassen PR, Wiesmüller L, Wells SI. Nucleic Acids Res. 2011 Sep 1;39(17):7465-76.
• Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Takiar V, Nishio S, Seo-Mayer P, King JD Jr, Li H, Zhang L, Karihaloo A, Hallows KR, Somlo S, Caplan MJ.Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2462-7.
• Telling kidneys to cease and decyst. Takiar V, Caplan MJ.Nat Med. 2010 Jul;16(7):751-2.
• Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo. Wise-Draper TM, Mintz-Cole RA, Morris TA, Simpson DS, Wikenheiser-Brokamp KA, Currier MA, Cripe TP, Grosveld GC, Wells SI. Cancer Res. 2009 Mar 1;69(5):1792-9.
• DEK proto-oncogene expression interferes with the normal epithelial differentiation program. Wise-Draper TM, Morreale RJ, Morris TA, Mintz-Cole RA, Hoskins EE, Balsitis SJ, Husseinzadeh N, Witte DP, Wikenheiser-Brokamp KA, Lambert PF, Wells SI. Am J Pathol. 2009 Jan;174(1):71-81.
• Coordinate regulation of Fanconi anemia gene expression occurs through the Rb/E2F pathway. Hoskins EE, Gunawardena RW, Habash KB, Wise-Draper TM, Jansen M, Knudsen ES, Wells SI. Oncogene. 2008 Aug 14;27(35):4798-808.
• Papillomavirus E6 and E7 proteins and their cellular targets. Wise-Draper TM, Wells SI. Front Biosci. 2008 Jan 1;13:1003-17. Review.
• Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Wise-Draper TM, Allen HV, Jones EE, Habash KB, Matsuo H, Wells SI. Mol Cell Biol. 2006 Oct;26(20):7506-19.
• The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7. Wise-Draper TM, Allen HV, Thobe MN, Jones EE, Habash KB, Münger K, Wells SI. J Virol. 2005 Nov;79(22):14309-17.
• Signal transduction by reactive oxygen species: alternative paradigms for signaling specificity. Fuh KC, Meneshian A, Patel CB, Takiar V, Bulkley GB. Surgery. 2002 Jun;131(6):601-12. Review.